Bicara Sets FORTIFY Trial at 1,500 mg Weekly Dose Versus Pembrolizumab, Mid-2027 Readout Target
Bicara advanced FICERA into its FORTIFY trial in HPV-negative head and neck cancer, selecting 1,500 mg weekly dosing and 2:1 randomization versus pembrolizumab. The company targets a mid-2027 response-rate top-line readout for potential 2028 approval and raised fresh capital to fund 2026 commercial buildout and expansion into colorectal and pancreatic cancer.
1. FORTIFY Trial Dose Selection and Design
Bicara refined its FORTIFY trial to focus on a 1,500 mg weekly dose of FICERA combined with pembrolizumab, removing the 750 mg arm. The study uses a 2:1 randomization against pembrolizumab monotherapy to assess response rate and durability in frontline HPV-negative head and neck cancer.
2. Global Enrollment and Approval Timeline
Enrollment accelerated after expansion into Europe, with Asia Pacific and South America planned next. The company expects about 60% of patients outside the U.S. and aims for a mid-2027 top-line response-rate readout that could underpin a 2028 regulatory submission.
3. Safety Profile and Efficacy Signals
FICERA has shown on-target EGFR inhibition adverse events such as acneiform rash, along with transient grade 1–2 mucosal bleeding and epistaxis. Patients achieving at least 80% tumor shrinkage demonstrated separation in duration of response, progression-free survival and overall survival curves, with activity across PD-L1 CPS subgroups and tumor sizes.
4. Financing and Pipeline Expansion
A recent capital raise will support 2026 commercial infrastructure and key hires ahead of a planned 2028 launch. Bicara is also running third-line colorectal cancer cohorts in monotherapy and pembrolizumab combination and is exploring pancreatic ductal adenocarcinoma settings based on EGFR and TGF-beta relevance.